Ideaya (IDYA) Climbs 6.39% on June 21

Equities Staff  |

Ideaya Biosciences Inc (NASDAQ: IDYA) has risen $0.79 (6.39%) and sits at $13.22, as of 11:57:37 est on June 21.

65,540 shares have exchanged hands.

The Company is up 17.92% over the last 5 days and shares gained 12.45% over the last 30 days.

Ideaya is set to release earnings on 2022-08-10.

For technical charts, analysis, and more on Ideaya visit the company profile.

About Ideaya Biosciences Inc

IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets.

To get more information on Ideaya Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Ideaya Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content